BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30288325)

  • 1. Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs.
    Bakacs T; Safadi R; Kovesdi I
    Hepatol Med Policy; 2018; 3():2. PubMed ID: 30288325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Clinically Validated, Broadly Active, Oral Viral Superinfection Therapy Could Mitigate Symptoms in Early-stage COVID-19 Patients.
    Bakacs T; Sandig V; Slavin S; Gumrukcu S; Hardy D; Renz W; Kovesdi I
    Infect Disord Drug Targets; 2022; 22(7):1-6. PubMed ID: 35440336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell therapy for chronic viral hepatitis.
    Bertoletti A; Tan AT; Koh S
    Cytotherapy; 2017 Nov; 19(11):1317-1324. PubMed ID: 28847469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
    Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
    Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B Gene Therapy Coming to Age.
    Soriano V
    AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Exploitation of Viral Interference.
    Kovesdi I; Bakacs T
    Infect Disord Drug Targets; 2020; 20(4):423-432. PubMed ID: 30950360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination.
    Bakacs T; Sandig V; Kovesdi I
    Cureus; 2022 Aug; 14(8):e28467. PubMed ID: 36176842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems.
    Nio Y; Sasai M; Akahori Y; Okamura H; Hasegawa H; Oshima M; Watashi K; Wakita T; Ryo A; Tanaka Y; Hijikata M
    Antiviral Res; 2019 Sep; 169():104537. PubMed ID: 31207277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of liver transplantation for viral hepatitis.
    Durand F; Francoz C
    Liver Int; 2017 Jan; 37 Suppl 1():130-135. PubMed ID: 28052618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis viruses and liver transplantation.
    Samuel D; Feray C; Bismuth H
    J Gastroenterol Hepatol; 1997 Oct; 12(9-10):S335-41. PubMed ID: 9407355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues.
    Papadopoulos N; Papavdi M; Pavlidou A; Konstantinou D; Kranidioti H; Kontos G; Koskinas J; Papatheodoridis GV; Manolakopoulos S; Deutsch M
    Ann Gastroenterol; 2018; 31(3):365-370. PubMed ID: 29720863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
    Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
    Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
    Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
    Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Therapy of Chronic Viral Hepatitis B, C and D.
    Schlaak JF
    J Pers Med; 2023 Jun; 13(6):. PubMed ID: 37373953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C.
    Sato K; Kobayashi T; Yamazaki Y; Takakusagi S; Horiguchi N; Kakizaki S; Kusano M; Yamada M
    Hepatol Res; 2017 Nov; 47(12):1346-1353. PubMed ID: 28422376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
    Kumar R; Singla V; Kacharya Sk
    Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.